Venetoclax was approved by the FDA and EMA in December 2016 for patients with previously treated CLL with del(17p13) and patients failing B cell receptor signaling inhibitors (EMA only), or who carry a TP53 mutation and are refractory to chemoimmunotherapy and BCR inhibitors recruited in the phase II M13-982 and M14-032 trials [58•]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.